Literature DB >> 17565435

Actigraphy in agitated patients with dementia. Monitoring treatment outcomes.

R Mahlberg1, S Walther.   

Abstract

Especially in pharmacotherapeutic research, a variety of methods to monitor behavioural and psychological symptoms of dementia (BPSD) are currently being discussed. To date, the most frequently used of these are clinical scales, which, however, are subjective and highly dependent on personnel resources. In our study, we tested the usefulness of actigraphy as a more direct and objective way to measure day-night rhythm disturbances and agitated behaviour. After a baseline assessment, 24 patients with probable dementia of the Alzheimer type (NINCDS-ADRDA) and agitated behaviour received either 3 mg melatonin (n=7), 2.5 mg dronabinol (n=7), or placebo (n=10) for two weeks. In addition, 10 young and 10 elderly healthy subjects were examined as a control group. Motor activity levels were assessed using an actigraph worn continuously on the wrist of the non-dominant hand. At the beginning and the end of the study, patients' Neuropsychiatric Inventory (NPI) scores were also assessed. In the verum group, actigraphic nocturnal activity (P=0.001), NPI total score (P=0.043), and NPI agitation subscale score (P=0.032) showed significant reductions compared to baseline. The treatment-baseline ratio of nocturnal activity (P=0.021) and treatment-baseline difference of the nocturnal portion of 24 h activity (P=0.012) were reduced. Patients' baseline activity levels were similar to those seen in healthy elderly subjects. Younger healthy subjects exhibited higher motor activity even at night. There was no correlation between actigraphy and NPI. Both actigraphic measures and the gold standard clinical scale were able to distinguish between the verum and placebo groups. However, because they did not correlate with each other, they clearly represent different aspects of BPSD, each of which reacts differently to therapy. As a result, actigraphy may well come to play an important role in monitoring treatment success in BPSD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565435     DOI: 10.1007/s00391-007-0420-z

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  31 in total

1.  Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy.

Authors:  Richard Mahlberg; Dieter Kunz; Igor Sutej; Klaus-Peter Kühl; Rainer Hellweg
Journal:  J Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.153

2.  Circadian activity rhythm in demented and non-demented nursing-home residents measured by telemetric actigraphy.

Authors:  Paula Paavilainen; Ilkka Korhonen; Jyrki Lötjönen; Luc Cluitmans; Marja Jylhä; Antti Särelä; Markku Partinen
Journal:  J Sleep Res       Date:  2005-03       Impact factor: 3.981

3.  Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.

Authors:  Richard Mahlberg; Sebastian Walther; Uta Eichmann; Ferenc Tracik; Dieter Kunz
Journal:  Arch Gerontol Geriatr       Date:  2006-09-11       Impact factor: 3.250

4.  Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging.

Authors:  R Hébert; M F Dubois; C Wolfson; L Chambers; C Cohen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-11       Impact factor: 6.053

5.  Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration.

Authors:  D G Harper; E G Stopa; A C McKee; A Satlin; P C Harlan; R Goldstein; L Volicer
Journal:  Arch Gen Psychiatry       Date:  2001-04

Review 6.  Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument.

Authors:  J Cohen-Mansfield
Journal:  Int Psychogeriatr       Date:  1996       Impact factor: 3.878

Review 7.  The Gottfries-Bråne-Steen scale: validity, reliability and application in anti-dementia drug trials.

Authors:  G Bråne; C G Gottfries; B Winblad
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Jan-Feb       Impact factor: 2.959

8.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly.

Authors:  Paola Fontana Gasio; Kurt Kräuchi; Christian Cajochen; Eus van Someren; Isabelle Amrhein; Mona Pache; Egemen Savaskan; Anna Wirz-Justice
Journal:  Exp Gerontol       Date:  2003 Jan-Feb       Impact factor: 4.032

10.  Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.

Authors:  Sebastian Walther; Richard Mahlberg; Uta Eichmann; Dieter Kunz
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

View more
  30 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  REVIEW: Apathy diagnosis, assessment, and treatment in Alzheimer's disease.

Authors:  Philippe H Robert; Emmanuel Mulin; Patrick Malléa; Renaud David
Journal:  CNS Neurosci Ther       Date:  2010-10       Impact factor: 5.243

Review 3.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 4.  [Delirium in the elderly].

Authors:  Manfred Gogol
Journal:  Z Gerontol Geriatr       Date:  2008-10-30       Impact factor: 1.281

Review 5.  'The clocks that time us'--circadian rhythms in neurodegenerative disorders.

Authors:  Aleksandar Videnovic; Alpar S Lazar; Roger A Barker; Sebastiaan Overeem
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

6.  Cross-Cutting Advancements Usher in a New Era for Motor Research in Psychosis.

Authors:  Vijay A Mittal
Journal:  Schizophr Bull       Date:  2016-08-18       Impact factor: 9.306

7.  Sleep Patterns and Neuropsychiatric Symptoms in Hospitalized Patients With Dementia.

Authors:  Kaloyan S Tanev; Andrew Winokur; Roger K Pitman
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2017-03-15       Impact factor: 2.198

Review 8.  Circadian rhythms in neurodegenerative disorders.

Authors:  Malik Nassan; Aleksandar Videnovic
Journal:  Nat Rev Neurol       Date:  2021-11-10       Impact factor: 42.937

9.  Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting.

Authors:  P H Robert; A Konig; S Andrieu; F Bremond; I Chemin; P C Chung; J F Dartigues; B Dubois; G Feutren; R Guillemaud; P A Kenisberg; S Nave; B Vellas; F Verhey; J Yesavage; P Mallea
Journal:  J Nutr Health Aging       Date:  2013       Impact factor: 4.075

10.  Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis.

Authors:  Anees Bahji; Arthi Chinna Meyyappan; Emily R Hawken
Journal:  Can J Psychiatry       Date:  2019-12-13       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.